
Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.
Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.
Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.
Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.
Celebrity Kim Kardashian West’s beauty brand raised $200m at a $1bn valuation from beauty brand Coty.
The genetic testing services provider has added a Samsung-led second close to a $23m first tranche that included a range of corporate investors.
Amit Kakar will supervise a Singapore office that will spearhead the pharmaceutical company's corporate venturing investments across Asia.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
ModiQuest's NET-targeted antibody spinoff closed a $20.9m round that also featured BrightGene, both having contributed to the first close last year.
Comcast, McKesson, Humana and Independence Health all scored exits as the health benefits services provider floated in an upscaled offering.